Skip to main content
Byron Homepage Hero Image

In the 2022 HF Guideline, ENTRESTO is recommended as a first-line treatment and to replace well-tolerated ACEi/ARB in patients with NYHA Class II–III HFrEF (Class 1 recommendation). ENTRESTO was also included as a treatment option for HFmrEF (LVEF 41%–49%) and select patients with HFpEF (LVEF 50%), particularly for patients with LVEF on the lower end of the spectrum (Class 2b recommendation).

*In PARAGON-HF, defined as LVEF 45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1

ACC, American College of Cardiology; ACEi, angiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, angiotensin II receptor blocker; HFmrEF, heart failure with mildly reduced ejection fraction; HFSA, Heart Failure Society of America; LAE, left atrial enlargement; LVH, left ventricular hypertrophy.

1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012